38 results about "Plant Lectins" patented technology

Described is a matrix to identify mother's milk missing fucosyltransferase-2 (FUT2) dependent glycans which comprise a line of a glycan binding protein such as a lectin or antibody suitable to bind 2'fucosyl-glycans and a line of a positive control to bind a mother's milk protein. For instance, this matrix is porous and allows for transport by capillary force of compounds of mother's milk such asglycoproteins. Especially, the glycan binding protein is the plant lectin from Ulex europaeus. A diagnostic kit comprising one or more of such matrices and a device suitable to receive such a matrix provided with a milk application window and a read-out window has been described as well. Finally a kit-of-parts comprising such a diagnostic kit and one or more feeding doses of 2'fucosyl-glycans hasbeen disclosed.

The invention relates to a glucose-responsive nitrile polyphosphine hydrogel and a method for preparing the same. The method utilizes interaction between nitrile polyphosphine containing glucose side groups and lectin concanavalin A (Concanavalin A, Con A) to obtain a hydrogel system with different crosslinking degrees and water contents through the proportion increase of the glucose side groups and the selection of a second proper substituting group and a third proper substituting group and other means; and the nitrile polyphosphine hydrogel system has glucose responsiveness, biocompatibility and biodegradability, and can be used for intelligent release of insulin.

The invention discloses a human lectin / human lectin-like chip for glycosylation detection in the field of biological sciences and a preparation method, which is constructed based on recombinant human lectin / human lectin-like protein. The recombinant proteins are 60 kinds of human lectin / human lectin-like proteins capable of recognizing and binding different sugar groups. Compared with the traditional plant lectin chip, the human lectin / human lectin chip has more specific recognition ability and stronger binding ability to complex glycoforms of higher vertebrate samples. Human lectin / human lectin-like chips provide a new technology platform for glycomics research and can be widely used in glycosylation research of humans or other mammals.

The subject invention concerns materials and methods for treating or preventing disease and conditions associated with various sulfatase enzymes that are defective or that are not properly expressed in a person or animal. In one embodiment, the disease is Sanfilippo A (MPS-IIIA) disease. The subject invention also concerns materials and methods for treating or preventing multiple sulfatase deficiency (MSD) in a person or animal. Compounds of the invention include a fusion protein comprising i) a mammalian sulfatase, or an enzymatically active fragment or variant thereof, and ii) a plant lectin or a binding subunit thereof. In a specific embodiment, the mammalian sulfatase is a human sulfatase, or an enzymatically active fragment or variant thereof. Polynucleotides encoding the fusion proteins are also contemplated for the subject invention. The subject invention also concerns materials and methods for producing proteins of the invention.

The invention discloses the use of a phytohemagglutinin PHA-L in the preparation of anti-coronavirus drugs. The present invention has been verified by experiments and found that the phytohemagglutinin PHA-L has better anti-highly pathogenic coronavirus activity, and can simultaneously Inhibition of SARS-CoV-2, SARS-CoV, MERS-CoV virus activity, shows that the phytohemagglutinin PHA-L can be used in the preparation of anti-coronavirus drugs, and has important prevention and / or treatment of high pathogenicity Application prospects of coronavirus infection.

The invention relates to the field of natural medicine, in particular to compound phytolectin and a preparation method and application thereof. The compound phytolectin is prepared from pseudo-ginseng, eucommia ulmoides, root of kudzu vine, rehmannia, root of red-rooted salvia, kelp and silverweed cinquefoil root leaves, wherein the compound phytolectin contains the components of salvianic acid, salvia miltiorrhiza flavones, notoginsenoside, rehmannia saponin, rehmannin, laminaran, pueraria flavones and eucommia ulmoides terpene. Pharmacological experiments prove that the compound phytolectinhas an ideal therapeutical effect for hypertension, when the compound phytolectin is cooperatively used with hypotensive drugs, the antihypertensive efficacy is further strengthened and is obviously superior to exclusive use of hypotensive drugs, and the toxic and side effects such as edema of hypotensive drugs after cooperative use are greatly reduced. Moreover, the compound phytolectin is a natural preparation, is safe and reliable to use, is applicable for various types of hypertension patients, and is extremely suitable for current clinical requirements.